Business Wire

Yubico More than Doubles Global Reach of YubiKeys for Enterprises to 175 Countries and 24 Territories, Simplifying Passwordless at Scale

Share

Expansion of YubiKey as a Service subscription and YubiEnterprise Delivery supports rising demand for streamlined, cost-effective phishing-resistant deployments

Yubico (NASDAQ STOCKHOLM: YUBICO), the leading provider of hardware authentication security keys, today announced the expanded availability of YubiKey as a Service to all countries in the European Union (EU). This allows organizations to be more agile and flexible in their adoption of phishing-resistant YubiKeys, and builds upon the company's existing reach in markets such as the United States, Canada, Japan, Singapore, Australia, India and the UK.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520271350/en/

Additionally, the company announced the expanded availability of YubiEnterprise Delivery across 117 new locations around the world. Now totalling 199 locations (175 countries and 24 territories), this more than doubles existing delivery coverage of YubiKeys to both office and remote users in a fast and turnkey way.

“Enterprises today are facing evolving cyber threats like Artificial Intelligence (AI)-driven phishing attacks,” said Jeff Wallace, senior vice president of product at Yubico. “By expanding our global reach of YubiKey as a Service and YubiEnterprise Delivery to 175 countries, we’re accelerating our ability to deliver and deploy device-bound passkey solutions that address the biggest threat facing businesses today from stolen login credentials. This expansion enables us to meet growing demand and accelerates adoption – enabling faster, more affordable delivery of pre-configured YubiKeys to markets like the EU and APJ, where regulatory pressures for phishing-resistant authentication are intensifying.”

Seamless user onboarding of YubiKeys with YubiKey as a Service

Rolling out phishing-resistant, passwordless security just got easier for all EU countries through the expansion of YubiKey as a Service. This innovative service provides enterprises with flexibility and simplifies the acquisition and fast roll out of phishing-resistant multi-factor authentication (MFA) with impactful cost savings. The Yubico Enrollment Suite, available exclusively through this service, now enables enterprises in these markets to accelerate passwordless adoption and seamless user onboarding with pre-configured keys to their users. This includes Yubico FIDO Pre-reg for factory-programmed, pre-registered keys as well as YubiEnroll client for in-person onboarding via Okta and Microsoft Entra ID – with more identity providers (IdPs) to follow.

Through these offerings, Yubico is aligning security with operational efficiency– helping organizations future-proof their workforce against evolving phishing threats.

Turnkey global delivery: YubiEnterprise Delivery

Getting hardware security keys into users’ hands – anywhere – is critical and needs to be fast and easy. As part of YubiKey as a Service, YubiEnterprise Delivery helps organizations achieve this by providing IT teams with powerful capabilities to easily manage the delivery of hardware security keys to users, while accelerating the adoption of strong authentication.

Additionally, organizations gain critical visibility into available inventory and consumption patterns of YubiKeys to ensure identification of any gaps in protection against phishing attacks. YubiEnterprise Delivery will continue to make it easy and flexible for enterprises to adopt phishing-resistant MFA and passwordless that stops account takeovers and credential phishing threats.

For more information on YubiKey as a Service and YubiEnterprise Delivery, visit yubico.com or contact our team today. For customers with a need to ship to more countries not currently on the supported list, reach out to your local Yubico representative here.

About Yubico

Yubico (NASDAQ STOCKHOLM: YUBICO), the inventor of the YubiKey, offers the gold standard for phishing-resistant multi-factor authentication (MFA), stopping account takeovers in their tracks and making secure login easy and available for everyone.

Since the company was founded in 2007, it has been a leader in setting global standards for secure access to computers, mobile devices, servers, browsers, and internet accounts. Yubico is a creator and core contributor to the FIDO2, WebAuthn, and FIDO Universal 2nd Factor (U2F) open authentication standards, and is a pioneer in delivering modern, hardware-based passkey authentication security at scale to customers in over 160 countries.

Yubico’s solutions enable passwordless logins using the most secure form of passkey technology. YubiKeys work out-of-the-box across hundreds of consumer and enterprise applications and services, delivering strong security with a fast and easy experience.

As part of its mission to make the internet more secure for everyone, Yubico donates YubiKeys to organizations helping at-risk individuals through the philanthropic initiative, Secure it Forward. The company is headquartered in Stockholm and Santa Clara, CA. For more information on Yubico, visit us at www.yubico.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250520271350/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release

Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release

IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye